论文部分内容阅读
药理试验证明紫杉醇能有效抑制多种人癌细胞，包括ＫＢ细胞、ＨＣＴ－８、Ａ２７８０及ＭＣＦ－７细胞的生长，ＩＣ５０分别为０．００１９，０．００３６及０．０１μｇ／ｍｌ。实验治疗指出，紫杉醇对黑色素瘤Ｂ－１６，Ｗａｌｋｅｒ癌肉瘤及对裸鼠的人卵巢癌异种移植瘤的生长有明显抑制作用。药理研究显示紫杉醇可促进微管蛋白聚合并抑制其解聚；明显影响Ｌ－１２１０细胞的周期移行，使细胞阻断在Ｇ２＋Ｍ期。此外，还出现多倍体细胞群体。药代动力学参数：ｔ１／２α为０．１２ｈ，ｔ１／２β为５．０２ｈ，ＡＵＣ为１１．８２（μｇ·ｈ）／ｍｌ，Ｖｃ为０．５０Ｌ／ｋｇ，ＣＬｓ为０．４２Ｌ／（ｈ·ｋｇ）
Pharmacological tests show that paclitaxel can effectively inhibit the growth of a variety of human cancer cells, including KB cells, HCT-8, A2780 and MCF-7 cells with IC50 of 0.0019, 0.0036 and 0.01 μg / ml, respectively. Experimental treatment pointed out that paclitaxel significantly inhibited the growth of melanoma B-16, Walker Carcinosarcoma and human ovarian cancer xenografts in nude mice. Pharmacological studies have shown that paclitaxel can promote tubulin polymerization and depolymerization; significantly affect the cycle of L-1210 cells, blocking cells in the G2 + M phase. In addition, polyploid cell populations also appear. Pharmacokinetic parameters: t1 / 2α 0.12h, t1 / 2β 5.02h, AUC 11.82 (μg · h) / ml, Vc 0.50 L / kg, CLs 0.42 L / ( h · kg)